PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24127927-2	2013	We undertook a prospective study to determine the influence of a 45-day course of aspirin therapy on circulating and intraplatelet levels of selected proangiogenic (vascular endothelial growth factor [VEGF]) and antiangiogenic (thrombospondin-1 [TSP-1]) proteins, and platelet protein release in women diagnosed with breast cancer who were receiving tamoxifen therapy.	Aspirin	82-89	thrombospondin 1	Homo sapiens	246-251	
24127927-3	2013	Initiation of aspirin therapy increases serum and intraplatelet levels of TSP-1 without a corresponding increase in VEGF levels.	Aspirin	14-21	thrombospondin 1	Homo sapiens	74-79	
24127927-4	2013	Following aspirin therapy, VEGF levels decreased (relative to pretreatment levels) while TSP-1 returned to pretreatment levels.	Aspirin	10-17	thrombospondin 1	Homo sapiens	89-94	
24127927-6	2013	Aspirin use also decreased thrombin receptor mediated release of TSP-1 and VEGF from platelets.	Aspirin	0-7	thrombospondin 1	Homo sapiens	65-70